1,721,106 research outputs found
Mesenchymal stem cell therapy and cardiac function: clinical experience in patients with myocardial infarction?
No full textMesenchymal stem cell therapy and cardiac function: clinical experience in patients with myocardial infarction?
No full textDo stem cells in the heart truly differentiate into cardiomyocytes?
No full textChronic congestive heart failure (CHF) is a common consequence of heart muscle or valve damage and remains a major cause of morbidity and mortality worldwide. There are increasing interests to treat cardiac failure by stein cell-based therapy. Many types of stem cells or progenitor cells have been suggested for cellular therapy of heart failure. While stem cell-based therapy was initially thought to be achieved by transdifferentiation of stem cells into myocardial cells including cardiomyocytes it has become clear that this may be rather an infrequent event. Instead cardiac regeneration may result from vascular differentiation of stem cells or even from stem cell-mediated reverse remodelling. Thus the term stem cell-mediated cardiac regeneration covers the spectrum from stem cell transdifferentiation into cardiomyocytes to cell-mediated pharmacotherapy. In this review we revise stem cell-based cardiac regeneration both in experimental models and in clinical application. We have limited our discussion on some selected types of stem cells, with particular emphasis on their differentiation potential, current status and perspectives on their future applications. (C) 2007 Elsevier Inc. All rights reserved
An integrated approach using patient-specific induced pluripotent stem cells and protein biochemistry to study Vici syndrome associated cardiomyopathy
No full textHuman spermatagonial stem cells: a novel therapeutic hope for cardiac regeneration and repair?
No full textCardiac Progenitor Cells and their Therapeutic Application for Cardiac Repair
No full textHeart disease is the principal cause of death in humans. Stem cell-based therapy for heart regeneration has long been seen as a potential application since the heart lacks adequate intrinsic regenerative potential. In the cardiovascular field, clinical trials have already been carried out by implantation of both bone marrow-derived stem cells and cardiac resident progenitor cells derived from the adult heart tissue into the injured myocardium to restore the functionality of the heart after damage. However, before a robust stem and progenitor cell-based therapy for cardiovascular diseases can be applied in the clinical setting, more research is necessary to generate sufficient quantities of functional cardiomyocytes from stem cells and to understand behavior of cardiomyocytes upon transplantation. A comprehensive understanding of the developmental processes involved in cardiogenesis might support further investigations in more efficient cell-based regeneration therapies. This review discusses the molecular aspects of cardiogenesis during early development and links the insights with the in vitro generation of cardiac progenitor cells as well as functional cardiomyocytes. Furthermore, we discuss the advantages of cardiac progenitor cells and cardiomyocytes derived from pluripotent stem cells, cardiac resident stem cells in regenerative applications to cope with the damaged heart.Open-Access-Publikationsfonds 201
RBM20 deficiency prevents expression of the mature N2B isoform of titin in cardiomyocytes derived from human induced pluripotent stem cells
No full textRBM20 deficiency prevents expression of the mature N2B isoform of titin in cardiomyocytes derived from human induced pluripotent stem cells
No full textLoss of beta1 integrin function results in upregulation of connexin expression in embryonic stem cell-derived cardiomyocytes
No full textshow that loss of beta 1 integrin function affects connexin (Cx) expression in embryonic stem (ES) cell-derived cardiomyocytes. Both loss of beta 1 integrin function and inhibition of integrin clustering by RGD peptides in wild type ES cells correlated with upregulated expression of gap junctional proteins in ES-derived cardiomyocytes. The upregulation of connexin transcript levels in beta 1 integrin-deficient cells is paralleled by a higher fraction of cells co-expressing Cx40 and Cx43. These observations demonstrate that the expression of connexins in developing cardiomyocytes is correlated to integrin-dependent mechanisms. Further, we found that upregulated cardiac connexin expression in beta 1 integrin-deficient cells is related to Rho- and Wnt-dependent pathways. beta 1 integrin-deficient cardiac cells displayed high levels of cytoplasmic gamma- and beta-catenins throughout the differentiation period. The administration of lithium, an activator of beta-catenin-dependent pathways, resulted in up-regulated connexin mRNA levels in wild type cardiomyocytes at intermediate, but not at early stages, indicating that the effects are restricted to advanced stages of cardiac differentiation. On the other hand, inhibition of Rho-dependent integrin signaling by treatment of cardiac cells with exoenzyme C3 resulted in immediate up-regulation of cardiac connexin transcript levels at early differentiation stages. Our data indicate that integrin function affects connexin expression in cardiomyocytes via direct effects on RhoA-dependent signaling mechanisms at early differentiation stages and of beta-catenin/Wnt-dependent pathways at advanced stages
- …
